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Cationic antimicrobial peptides are essential components of the innate immune system. As a major family of mammalian anti-
microbial peptides, defensins are expressed mainly by mucosal epithelial cells and promyelocytes. Despite the capacity to kill a
broad spectrum of bacteria through physical disruption of membranes, most defensins show substantially reduced antibacterial
activities in the presence of monovalent and divalent cations, thereby limiting their therapeutic potential, particularly for the
treatment of systemic infections. Genome-wide computational screening of the rat genome led to the identification of the gene
for a novel-defensin-related peptide that we termed rattusin. Rattusin shares a highly conserved signal and prosequence with
mammalian-defensins, but instead of the canonical -defensin six-cysteine motif, rattusin consists of five cysteines with a dis-
tinctive spacing pattern. Furthermore, rattusin is preferentially expressed in Paneth cells of the distal small intestine with potent
antibacterial activity against a broad range of Gram-negative and Gram-positive bacteria, including antibiotic-resistant strains.
TheMICs were mostly in the range of 2 to 4M, with no appreciable toxicity to mammalian cells at up to 100M. In contrast to
classical- and-defensins, rattusin retained its activity in the presence of physiological concentrations of NaCl andMg2,
making it an attractive antimicrobial candidate for both topical and systemic applications.
The emergence of antibiotic-resistant pathogens is a majorhealth crisis worldwide (1), and there is an urgent need to
develop novel antimicrobial drugs against resistant microbes. As
critical components of innate defense mechanisms, cationic anti-
microbial peptides are capable of killing a broad spectrum of bac-
teria, including antibiotic-resistant strains with potential for fur-
ther exploration as a new class of antimicrobial drugs (2–4). Two
major families of antimicrobial peptides, namely, defensins and
cathelicidins, exist in vertebrates (5–8). Unlike cathelicidins,
which are often devoid of cysteines, defensins are characterized by
six cysteines in well-defined spacing patterns forming intramolec-
ular disulfide bonds whose pairings define the three mammalian
defensin subfamilies (Fig. 1). Besides the well-described -, -,
and -defensins with six characteristic cysteine residues, two ad-
ditional subfamilies of -defensin-related cryptdin-related se-
quence (CRS) peptides (CRS1C and CRS4C) exist that contain 9
and 11 cysteines, respectively (9). In mammals, -defensins are
produced mainly by promyelocytes and intestinal Paneth cells,
whereas -defensins are widely expressed by diverse mucosal ep-
ithelial cells (5–7). In contrast, -defensins are uniquely expressed
in Old World monkey promyelocytes and accumulate in neutro-
phils and monocytes, and CRS peptides are exclusive to mice and
are abundant in Paneth cell secretory granules (5–7, 9).
Defensins possess pleotropic functions in host defense. In ad-
dition to broad-spectrum antibacterial, antiviral, and antifungal
activities, certain - or -defensins may be chemotactic for den-
dritic, mast, monocytic, and T cells (5–7) and may induce matu-
ration of dendritic cells (10). Defensins help in wound healing by
inducing vascularization, promoting proliferation of epithelial
and fibroblast cells, and augmenting wound closure (5–7, 10). In
addition, several human neutrophil -defensins are capable of
neutralizing bacterial toxins (11, 12).
Defensins are encoded by distinct genes and synthesized ini-
tially as precursors with conserved signal and propeptide se-
quences (Fig. 2). Biologically active, mature defensins are gener-
ated through specific proteolytic cleavage events within the
prosequence. For example, matrix metalloproteinase 7 (MMP7)
processes Paneth cell -defensin precursors into biologically ac-
tive peptides in mice (13), whereas elastase and proteinase 3 ap-
pear to be the convertases for neutrophil -defensin precursors in
humans (14) and an intracellular proteoglycan, serglycin, is in-
volved in the retention of mature peptides in neutrophil granules
(15). Human intestinal -defensin (HD5), on the other hand, is
processed by trypsin (16).
The innate immune role of Paneth cell -defensins in protect-
ing enteric infections has been well documented. Transgenic mice
that express the gene for HD5 are immune to oral Salmonella
enterica serovar Typhimurium (S. Typhimurium) infections (17).
Also, mice lacking the gene for MMP7 are more susceptible to
systemic S. Typhimurium disease and are defective in the clear-
ance of enteric infection because of an inability of Paneth cells to
produce mature -defensins (13). A deficiency in the synthesis of
intestinal -defensins was also recently linked to the pathogenesis
of ileal Crohn’s disease (18). In addition, Paneth cell -defensins
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play a critically important role in regulating the composition of
the ileal microbiota (19) with potential implications in health and
disease (20).
Although mature defensins are broadly active against both
Gram-positive and -negative bacteria, their potential as therapeu-
tics has been hampered by a substantial loss of antibacterial activ-
ity in the presence of physiological concentrations of salts (5–7). It
is worth noting that although they are essential for chemotaxis
(21) and peptide resistance to proteolysis (22), the integrity of
conserved disulfide arrays and the spatial structure they impose
are not, per se, critical to the microbicidal activity of - and -de-
fensins but are required for that of -defensins (23).
Through a comprehensive genome-wide computational
screening of the genomes of several phylogenetically distant ani-
mal species, including primates, rodents, and dogs, we identified a
unique -defensin-related sequence in the rat (24), termed rat-
tusin for Rattus defensin. Rattusin belongs to a new defensin sub-
family with a unique cysteine spacing pattern that is distinct from
that of all other known peptides (24) (Fig. 1). We now show that
the gene for rattusin is abundantly expressed in Paneth cells of the
distal small intestine. Desirably, synthetic rattusin possesses po-
tent bactericidal activities that are insensitive to physiological con-
centrations of NaCl and Mg2, making it an attractive novel anti-
microbial candidate.
MATERIALS AND METHODS
Reverse transcriptase (RT)-PCR. Different segments of the gastrointes-
tinal tract were collected from healthy 2-month-old Sprague-Dawley rats.
Total RNA was extracted with TRIzol (Invitrogen). For each RNA sample,
4 g was reverse transcribed with random hexamers and SuperScript II
reverse transcriptase (Invitrogen) according to the manufacturer’s in-
structions. The subsequent PCR was carried out as described previously
FIG 1 Schematic drawing of the structure of a mammalian defensin precursor. Although all classical -, -, and -defensins contain six cysteines with different
disulfide arrays, three subfamilies of-defensin-related sequences (defa-rs) with a different number and spacing pattern of cysteines have been found in intestinal
Paneth cells of mice (CRS1C and CRS4C) and rats (rattusin). The prosequences of defensins are highly conserved within but not between subfamilies, except for
-defensins, whose prosequences are variable as well. Biologically active, mature sequences of defensins are released from proforms through proteolytic cleavage.
FIG 2 Amino acid sequence alignment of rattusin with representative -defensins and related peptides in rodents and humans. Dashes were inserted to
maximize the alignment. Conserved amino acids are shaded, and mature sequences are underlined. Vertical arrows indicate the known start sites of mature
peptides. The length of each mature peptide is also indicated. The signal peptides and prosequences of the peptides are conserved, whereas carboxyl-terminal
mature peptides are diversified. Note that the spacing pattern of cysteine residues in rattusin differs from those of all other defensins and defensin-related
peptides. Abbreviations: rDefa6, rat -defensin 6; RatNP4, rat neutrophil peptide -defensin 4; DEFA5/HD5, human -defensin 5.
Patil et al.
1824 aac.asm.org Antimicrobial Agents and Chemotherapy
(24). Briefly, 1/40 of the first-strand cDNA was used to amplify rattusin,
MMP7, three isoforms of trypsin, and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) with gene-specific primers (Table 1). The identities
of PCR products were confirmed by agarose gel electrophoresis, followed
by gel purification, cloning into T/A cloning vector, and direct DNA se-
quencing.
In situ hybridization. A proximal ileal segment was freshly collected
from a healthy 2-month-old Sprague-Dawley rat and fixed for 4 h in
phosphate-buffered formalin solution. Tissue preparation and in situ hy-
bridization were done largely as described previously (25). Briefly, each
paraffin-embedded specimen was cut into 10-m sections and fixed on
poly-L-lysine-treated slides. After dewaxing and rehydration, the slides
were treated with 2 g/ml proteinase K for 30 min at 37°C, followed by
prehybridization at 55°C for 1 h in 50% deionized formamide–2.25
SSPE (300 mM NaCl, 20 mM NaH2PO4, 2 mM EDTA, pH 7.4)–10%
dextran sulfate,–2.5Denhardt’s solution,–100g/ml sheared and dena-
tured herring sperm DNA–100 g/ml yeast tRNA–5 mM dithiothrei-
tol– 40 U/ml RNase inhibitor. Slides were then hybridized in a humidified
chamber at 42°C overnight in the same solution containing 1g/ml alka-
line phosphatase-conjugated, digoxigenin (DIG)-labeled sense or anti-
sense RNA probe for rattusin. After the slides had been washed twice for 5
min each time with 3 SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium
citrate) at room temperature, once for 20 min in 2 SSC, and once for 1
h at 57°C with 0.1 SSC, the DIG Nucleic Acid Detection kit (Roche
Applied Science) was used to capture the rattusin mRNA signal in the
blocking solution containing 1.25 U/ml of alkaline phosphatase-conju-
gated anti-DIG Fab fragments. The color was developed in the solution
containing 5 mM MgCl2, 0.2 mM 5-bromo-4-chloro-3-indolylphosphate
(BCIP), and 0.2 mM nitroblue tetrazolium (NBT) salt overnight at room
temperature. After being mounted in VectaMount Mounting Medium
(Vector Laboratories), the slides were examined with an Olympus BX51
fluorescence microscope equipped with a DP72 digital camera.
To make sense and antisense rattusin RNA probes, a 126-bp segment
located in the less conserved mature region of rattusin mRNA was ampli-
fied by RT-PCR from a rat ileal RNA sample with the following primers:
forward, GTAAGAAGGACCTTGCAGTG; reverse, CTCATCCTTGGGG
TCCATGT. The PCR product was then cloned into the pGEMT-Easy
vector (Promega) and sequenced to confirm its identity. The DIG RNA
Labeling kit (Roche Applied Science) was used to label sense and antisense
RNA probes with DIG-11-UTP by in vitro transcription with SP6 and T7
RNA polymerases, respectively.
Preparation of defensin peptides. Since MMP7 preferentially cleaves
the intestinal defensin sequences prior to leucine in mice (26–28), we
reasoned that mature rattusin is likely to start from the first leucine after
the prosequence. Therefore, a putatively mature sequence of 31 amino
acids (LRVRRTLQCSCRRVCRNTCSCIRLSRSTYAS) was chemically
synthesized in the reduced form by standard solid-phase synthesis, puri-
fied by reverse-phase high-pressure liquid chromatography (RP-HPLC)
to95% purity, and purchased from Bio-Synthesis Inc. (Lewisville, TX).
The mass of the peptide was confirmed by matrix-assisted laser desorp-
tion ionization–time of flight mass spectrometry (MS) with Voyager DE-
PRO (Applied Biosystems, Foster City, CA) housed in the Recombinant
DNA/Protein Core Facility at Oklahoma State University.
To oxidize reduced rattusin, a 0.1-mg/ml concentration of the peptide
was exposed to O2 gas for 5 min in 50 mM Tris, pH 8.0, and stirred gently
for 48 h at room temperature with the cap open as described previously
(28). Following air oxidation, refolded rattusin was purified by RP-HPLC
on a Vydac C18 column (4.6 by 250 mm; Grace Vydac, Hesperia, CA) and
a BioLogic DuoFlow liquid chromatography system (Bio-Rad, Hercules,
CA). Buffer A consisted of 5% acetonitrile and 0.18% trifluoroacetic acid
(TFA), and buffer B consisted of 90% acetonitrile and 0.15% TFA. The
gradient used was 0 to 60% buffer B over 90 min at a flow rate of 1 ml/min.
Eluted peptide was lyophilized and stored at80°C until use. The peptide
was reconstituted in 0.01% acetic acid and quantified by measuring UV
absorbance at 280 nm on the basis of the extinction coefficients of tyrosine
and cysteines present in rattusin (29).
Recombinant mouse Crp4 was produced as an N-terminally six-histi-
dine-tagged fusion protein in Escherichia coli and purified by RP-HPLC as
previously described (27, 30). Human intestinal -defensin 5 (HD5) was
chemically synthesized and oxidized as described previously (31).
Bacterial culture and antibacterial assays. All bacterial strains, in-
cluding Staphylococcus aureus ATCC 25923, S. aureus ATCC BAA-39, S.
aureusATCC 43300, ListeriamonocytogenesATCC 19115, E. coliO157:H7
ATCC 700728, S. Typhimurium ATCC 14028, S. Typhimurium DT104
ATCC 700408, and Klebsiella pneumoniae ATCC 13883 were purchased
from either the American Type Culture Collection (ATCC; Manassas,
VA) or MicroBiologics (St. Cloud, MN). Bacteria were grown in tryptic
soy broth (TSB) overnight and subcultured for 3 to 4 h at 37°C in a shaking
incubator to the mid-log phase. To study the antibacterial spectrum, a
modified broth microdilution assay was used (32). Briefly, mid-log-phase
bacteria were washed with 25 mM sodium phosphate buffer, pH 7.4, and
suspended to 5  105 CFU/ml in 25 mM sodium phosphate, pH 7.4,
containing 5% TSB with or without 100 mM NaCl. Bacteria (90 l) were
then dispensed into a 96-well tissue culture plate and serial 2-fold dilu-
tions of rattusin or Crp4 (10 l) were added in duplicate. After overnight
incubation at 37°C, the MIC of each peptide was determined as the lowest
peptide concentration that gave no visible bacterial growth.
To study the effect of peptide exposure time on bacterial viability, a
time-kill assay was used (32). Rattusin, cryptin-4, and HD5 were incu-
bated with 90 l of 5 105 CFU/ml S. aureus ATCC 25923, E. coli ATCC
25922, or E. coli O157:H7 ATCC 700728 in 25 mM sodium phosphate
buffer, pH 7.4, containing 1% TSB with or without 100 mM NaCl. Fol-
lowing incubation at 37°C for 10, 30, 60, 120, or 240 min, bacteria were
diluted rapidly with ice-cold phosphate-buffered saline and serially plated
onto tryptic soy agar plates. Viable bacteria were counted after overnight
incubation at 37°C. The effect of Mg2 on antibacterial activity was stud-
ied by incubating rattusin or Crp4 for 4 h with 90 l of S. aureus (5 105
CFU/ml) at 2 M each or with E. coli O157:H7 at 4 M each in 25 mM
sodium phosphate buffer–1% TSB, pH 7.4, containing 0, 1, 2, or 5 mM
MgCl2.
Cytotoxicity assay.The toxicity of rattusin to human Caucasian colon
adenocarcinoma (Caco-2) cells (ATCC, Manassas, VA) was measured
with alamarBlue dye (BioSource, Inc., Camarillo, CA) as described previ-
ously (33, 34). Briefly, Caco-2 cells were seeded into the wells of a 96-well
plate at 5  104/ml of Dulbecco’s modified Eagle’s medium (DMEM)
with 10% fetal bovine serum (FBS) and grown overnight in a humidified
TABLE 1 Primers sequences used for RT-PCR analysis of rattusin and intestinal proteases
Gene product Forward primer Reverse primer GenBank accession no.
Product
size (bp)
Rattusin GAAGACACTTGTCCTCCTTTCTG ATGTGGACCTTGATAGCCGATG AY623756 261
MMP7 AGTGGACAAACTGAGGGAAATG ACTAAGAACCGAGGCAAGTCTG NM_012864 210
Anionic trypsin GTTGGAGGATACACCTGCCCG CTTGATGATCTTGGCAGCATTG NM_012635 213
Mesotrypsin GGAGGATACACCTGCCAAGAGA CTTGATGATCTTGGCAGCATTG NM_001108626 210
Cationic trypsin ATTGATGTCGTTGAGGGTGGT GAAGCAGTGAAGGGTAGTTCGT NM_173127 244
GAPDH GTGAAGGTCGGAGTGAACG GAGATGATGACCCTCTTGGC NM_017008 356
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5% CO2 incubator. Cells were washed once with DMEM, and then fresh
DMEM containing 100 M rattusin, Crp4, or chicken fowlicidin-1 (32,
33) in the presence or absence of 10% FBS was added. After 18 h of
incubation, 10 l of alamarBlue dye was added and the cells were incu-
bated for another 6 h at 37°C. The plate was read with excitation at 545 nm
and emission at 590 nm. The percentage of cell death was calculated as
[1  (Fpeptide  Fbackground)/(Facetic acid  Fbackground)]  100, where
Fpeptide is the fluorescence of cells exposed to 100M peptide, Facetic acid is
the fluorescence of cells exposed to 0.01% acetic acid only, and Fbackground
is the background fluorescence of 10% alamarBlue dye in cell culture
medium without cells.
RESULTS
Rattusin, an -defensin-related peptide, is preferentially ex-
pressed in the distal small intestine. Following a comprehensive
screening of the rat genome, we identified the gene for an orphan
-defensin-related protein known as defa-rs1 (24), which we now
term rattusin. The gene for rattusin is located within the -defen-
sin gene cluster in the rat genome, which surprisingly encodes no
-defensin-related CRS peptides seen in mice. Similar to the genes
for typical -defensins, the gene for rattusin is composed of two
short exons separated by a 572-bp intron, with the first exon en-
coding the 5= untranslated region (UTR) and preprosegment and
the second encoding a putatively mature peptide and the 3= UTR.
Although it is conserved in signal and prosequences with rodent
-defensins, the encoded rattusin peptide consists of 5 cysteines in
the carboxyl-terminal region, in contrast to the canonical 6-cys-
teine motif of classical mammalian defensins and the 9 or 11 cys-
teines of CRS peptides (Fig. 2). Furthermore, the cysteine spacing
pattern of rattusin is different from those of classical defensins or
CRS peptides (Fig. 2).
Rattusin mRNA is transcribed abundantly in the intestinal
tract of the rat (24). To analyze the rattusin expression pattern in
greater detail, RT-PCR was performed with RNA samples isolated
from different segments of the gastrointestinal tracts of 2-month-
old healthy rats. As shown in Fig. 3, rattusin was highly expressed
in the distal jejunum and the entire ileum, with peak expression in
the proximal ileum. The stomach, duodenum, cecum, or colon
showed no evident expression. The result is reminiscent of Crp4
and HD5, two Paneth cell-specific -defensins that also show a
similar expression pattern in the small intestine (35–37).
Paneth cell -defensin precursors are activated by trypsin in
humans (16) or by MMP7 in mice (13, 26). To begin identifying
the protease that mediates the activation of rattusin, we studied
the tissue expression patterns of MMP7 and three major isoforms
of trypsin (cationic trypsin, anionic trypsin, and mesotrypsin)
(38) in the rat gastrointestinal tract by RT-PCR. MMP7 was pref-
erentially expressed from the distal jejunum to the distal ileum,
coinciding with rattusin expression, whereas trypsin isoform
mRNAs were more localized to the duodenum (Fig. 3), suggesting
that MMP7, a Paneth cell-associated proteinase, is a more likely
prorattusin convertase, as is the case in mice (13, 26, 27). In agree-
ment with this, two serine residues, which are preferred MMP7
cleavage sites in rodent enteric-defensins (26, 27), are conserved
in rattusin but not in rat myeloid -defensin (RatNP4) (Fig. 2).
These findings also predicted that rattusin is produced by Paneth
cells at the base of small intestinal crypts.
To determine the cell type responsible for the expression of
rattusin, in situ hybridization was performed with rat proximal
ileal sections and DIG-labeled sense and antisense rattusin RNA
probes. The antisense rattusin RNA probe revealed positive brown
staining at the base of intestinal crypts, where the control sense
strand RNA probe showed no staining (Fig. 4), suggesting that
FIG 3 mRNA expression patterns of rattusin, MMP7, and three isoforms of
trypsin in the rat gastrointestinal tract by RT-PCR. The housekeeping gene for
GAPDH was used to normalize template input. Prox., proximal; Mid., middle.
FIG 4 Localization of rattusin mRNA in rat ileal crypts. In situ hybridization
was performed with rat ileal sections probed with rattusin-specific, DIG-la-
beled antisense (A) and sense (B) RNA probes, followed by anti-DIG antibody
reaction and color development. Note the positive staining throughout the
base of intestinal crypts (indicated by arrows) in panel A but not in panel B.
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rattusin is produced by Paneth cells, as are the Crp4 and HD5
enteric -defensins.
Rattusin has broad-spectrum, salt-insensitive antibacterial
activities. To evaluate the antibacterial activity of rattusin, we in-
ferred its mature sequence on the basis of the MMP7 cleavage
pattern of mouse CRS peptides (28) and synthesized the reduced
form of the deduced five-cysteine peptide, refolded the molecule
by air oxidation (28), and purified it by RP-HPLC. Because refold-
ing induced changes in the spatial structure and hydrophobicity of
rattusin compared to the reduced form, an approximately 5.5-
min difference in retention time existed between the two forms
(Fig. 5), enabling their separation. Refolded rattusin was assayed
for antibacterial activity against several representative Gram-neg-
ative and Gram-positive bacteria with a modified broth microdi-
lution assay with or without 100 mM NaCl (32). Rattusin exhib-
ited potent antibacterial activities, with MICs in the range of 2 to 4
M or 7.3 to 14.6 g/ml (Table 2). In most cases, rattusin was as
potent as Crp4, a highly bactericidal mouse Paneth cell-defensin
(39). Importantly, rattusin also displayed similar antibacterial ef-
ficiency against two strains of methicillin-resistant S. aureus
(MRSA) and against multidrug-resistant S. Typhimurium DT104
(Table 2). Importantly, the activity of rattusin remained largely
unchanged in the presence of NaCl, in sharp contrast to that of
Crp4, which was nearly completely abolished by salt (Table 2).
Disulfide bonds are not necessarily essential for the antibacte-
rial activity of most - and -defensins (5–7). To test whether
rattusin remains active in the reduced form, different concentra-
tions of reduced and refolded rattusin were incubated with E. coli
ATCC 25922 and S. aureus ATCC 25923 for 2 h in 10 mM phos-
phate buffer, pH 7.4, with or without supplementation with 100
mM NaCl. Bacterial viability was measured by quantitative plat-
ing. In the absence of NaCl, reduced rattusin showed a slightly
enhanced antibacterial activity against both E. coli and S. aureus
compared to that of the refolded form, with the bacteria becoming
more sensitive to reduced rattusin, particularly at low concentra-
tions (Fig. 6A and C). However, in the presence of 100 mM NaCl,
an obvious reduction of the killing of E. coli by reduced rattusin
was observed compared to that by the refolded peptide (Fig. 6B).
The reduction of the killing of S. aureus by the reduced peptide
became more pronounced (Fig. 6D). However, regardless of the
rattusin redox status, bacterial killing efficacy, and possibly MICs,
remained largely unchanged with or without NaCl, particularly at
high concentrations (Fig. 6). Although NaCl diminished the bac-
terial sensitivity to reduced rattusin and possibly the kinetics of
bacterial killing, its antibacterial potency, as measured by MICs,
was not greatly affected. Thus, the peptide conformation estab-
lished by intramolecular disulfide bonds does not appear to be a
critically important determinant of rattusin salt-insensitive anti-
bacterial activity. It is noteworthy that reduced rattusin remained
unoxidized in 2 to 4 h under the time-kill assay conditions, as
evidenced by the RP-HPLC profile (data not shown). Consistent
with data in Table 2, Crp4 had antibacterial potency similar to that
of rattusin when assayed in a low-ionic-strength environment but
was completely inactivate against both E. coli and S. aureus in 100
mM NaCl (Fig. 6).
To study the effect of peptide exposure time on bacterial kill-
ing, each of the representative species of Gram-negative and
Gram-positive bacteria was evaluated with the peptides by the
time-kill assay. When E. coli was exposed to 4 M refolded rat-
tusin, Crp4, and HD5 for 2 h, its survival was reduced by 3 logs in
the absence of exogenous NaCl (Fig. 7A), but in 100 mM NaCl, 4
h of exposure to rattusin was required to achieve maximum bac-
terial killing (Fig. 7B). As before, Crp4 and HD5 were completely
inactivated by 100 mM NaCl (Fig. 7B). A similar trend occurred
with S. aureus, with survival reduced by 2 logs after 4 h of exposure
to 2 M peptides (Fig. 7C), in which rattusin activity was unaf-
fected by 100 mM NaCl but Crp4 and HD5 were significantly
inhibited in the presence of salt (Fig. 7D). To study the effect of
salinity further, the antibacterial activity of rattusin was assayed in
the presence of increasing concentrations of NaCl, and the peptide
maintained its bactericidal effects against bothE. coli (Fig. 8A) and
S. aureus (Fig. 8B) at NaCl levels of up to 200 mM. Collectively,
these results showed that rattusin is a highly bactericidal -defen-
sin-related peptide with broad-spectrum, salt-insensitive activity.
Divalent cations such as Mg2often occur at 1 to 2 mM in most
biological fluids (40). At low concentrations, divalent cations are
known to inhibit the antibacterial activities of cationic peptides
(41, 42). To study the effect of Mg2 on their antibacterial activity,
rattusin and Crp4 were incubated with bacteria in the presence of













E. coli O157:H7 700728 2–4 2–4 2 16
S. Typhimurium 14028 4 8 8 16
S. Typhimurium DT104 700408 4 4–8 4–8 16
K. pneumoniae 13883 2–4 4–8 8 16
Gram positive
S. aureus 25923 4 4 1–2 16
L. monocytogenes 19115 4 4 8 16
S. aureus (MRSA) 43300 4 4 2 8
S. aureus (MRSA) BAA-39 4–8 4–8 1–2 16
a The antibacterial assay was performed in the presence or absence of 100 mM NaCl.
The MICs were obtained from two independent experiments.
FIG 5 RP-HPLC profile of reduced and oxidized rattusin. The reduced syn-
thetic peptide was refolded by air oxidation. Refolded rattusin was purified to
homogeneity by RP-HPLC. Note that there is an approximately 5.5-min de-
crease in the retention time of oxidized rattusin due to refolding.
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increasing concentrations of MgCl2. There was a dose-dependent
loss of the activity of Crp4 against E. coli, leading to complete
inactivation at 2 to 5 mM MgCl2 (Fig. 8C). In contrast, rattusin
activity was largely unaffected by MgCl2 (Fig. 8C). Against S. au-
reus, on the other hand, Mg2 failed to inhibit the activity of either
rattusin or Crp4 over the same concentration range (Fig. 8D).
Rattusin displays minimum cytotoxicity. To examine the cy-
totoxic effect of rattusin to intestinal epithelial cells, human
FIG 6 Antibacterial activities of reduced and oxidized forms of rattusin in the presence or absence of 100 mM NaCl. A colony counting assay was conducted
following 2 h of incubation of bacteria with each peptide in serial 2-fold dilutions in duplicate. (A) Activity against E. coli ATCC 25922 in the absence of NaCl.
(B) Activity against E. coli ATCC 25922 in the presence of NaCl. (C) Activity against S. aureus ATCC 25923 in the absence of NaCl. (D) Activity against S. aureus
ATCC 25923 in the presence of NaCl. Data shown are the means	 the standard errors of the means of a representative of two independent experiments.
FIG 7 Kinetics of killing of E. coli and S. aureus in the presence or absence of 100 mM NaCl by rattusin, Crp4, and HD5. E. coli O157:H7 ATCC 700728 was
incubated with 4M rattusin, Crp4, or HD5 or an equal volume of 0.01% acetic acid (control) in duplicate with (A) or without 100 mM NaCl (B) for 10, 30, 60,
120, or 240 min. S. aureus ATCC 25923 was incubated with or without each peptide at 2 M in duplicate in the absence (C) or presence (D) of 100 mM NaCl.
Surviving bacteria were plated and counted. Data shown are the means	 the standard errors of the means of two independent experiments.
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Caco-2 cells were treated with the peptide at 100 M for 24 h in
the presence or absence of 10% FBS. Fowlicidin-1 (100 M) was
used as a positive reference because it has shown significant cyto-
toxicity to mammalian cells (32). Similar to Crp4, rattusin lacked
cytotoxicity even at 100 M or 365 g/ml with or without FBS
under conditions in which fowlicidin-1 killed nearly 100% of the
Caco-2 cells (Fig. 9) or lysed human erythrocytes (data not
shown).
DISCUSSION
Rattusin is the only-defensin-related peptide in the rat that con-
tains five cysteine residues with a unique cysteine spacing pattern
that differs from that of all known defensins. It will be important
to determine its aggregation form and disulfide bonding pattern.
Our preliminary data revealed that, upon oxidative refolding, a
fraction of synthetic reduced rattusin peptides formed ho-
modimers and even oligomers (data not shown), suggesting that
four cysteine residues are likely to form two intramolecular disul-
fide bonds with the fifth cysteine involved in dimerization with
other rattusin molecules. However, the pairing between cysteines
appears to be somewhat random, as a mixture of disulfide isomers
was observed in refolded rattusin (data not shown). Nevertheless,
it is plausible that native mature rattusin is present in covalent
dimers or multimers in the rat intestinal tract, given earlier reports
on the dimerization of both - and -defensins and related pep-
tides consisting of an odd number of cysteines. For example,
mouse CRS peptides containing 9 or 11 cysteines form mixtures of
covalent homo- and heterodimers in vivo (28), and a mouse-de-
fensin peptide variant with 5 cysteines also dimerizes (43). Di-
meric CRS peptides are 2- to 4-fold more potent than their mo-
nomeric forms (28), and several canonical defensins with six
cysteines form noncovalent dimers or oligomers upon interaction
with bacterial membranes (44). Human intestinal -defensin
HD6, albeit with weak antibacterial activities, promotes mucosal
innate defense by assembling into nanonets to entrap and prevent
bacteria from attaching to and invading intestinal epithelial cells
(45). Oligomerization thus appears to potentiate antibacterial ac-
tivity. It will be interesting to determine the difference in antibac-
terial and other functional properties between monomeric and
multimeric forms if rattusin indeed oligomerizes, although only
monomeric rattusin purified through RP-HPLC was used in all of
our functional assays.
Refolded rattusin possesses potent, broad-spectrum antibacte-
rial activities. Furthermore, rattusin maintained potency against
both E. coli and S. aureus when the disulfide bonds were reduced,
reminiscent of most - and -defensins, whose antibacterial ac-
tivities appear to be independent of their redox status. In fact,
human -defensin 1 exhibits substantially enhanced antibacterial
potency when reduced (46), while CRS peptides show altered an-
tibacterial selectivity but not potency following the reduction of
FIG 8 Effect of salinity on the antibacterial activity of rattusin. E. coliO157:H7 ATCC 700728 (A, C) and S. aureusATCC 25923 (B, D) were incubated with 4 and
2 M rattusin, respectively, with increasing concentrations of NaCl (A, B) or MgCl2 (C, D) for 4 h. Surviving bacteria were plated and counted. Data shown are
the means	 the standard errors of the means of two or three independent experiments.
FIG 9 Absence of cytotoxicity of rattusin and Crp4 to Caco-2 cells. Cells were
incubated with 100 M rattusin, Crp4, or fowlicidin-1 in duplicate for 24 h
with or without 10% FBS. Cell viability was measured by an alamarBlue dye-
based method. The data shown are representative of two independent experi-
ments.
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disulfide bonds (28). The macrocyclic -defensins are exceptions
in that their bactericidal activities are nearly abolished when they
are reduced (23). Although the integrity of disulfide bonds and
spatial structure does not determine the antibacterial activities of
most defensins per se, the disulfide arrays are required for other
biological functions, such as chemotactic activities (21) and resis-
tance to proteolysis (47). However, it remains unknown whether
reduction of the disulfide bonds of rattusin impact its nonbacte-
ricidal activities.
In sharp contrast to Crp4, HD5, and most - and -defensins
(5–7), rattusin maintains its antibacterial activity in the presence
of physiological concentrations of NaCl and Mg2, a prerequisite
for potential therapeutics. Although -defensins, with a unique
cyclic structure, retain their antibacterial activity in the presence
of NaCl, reduction of the disulfide bonds diminishes their activity
(23). In the case of rattusin, salt insensitivity appears to be inde-
pendent of structure because the reduced form maintained the
antibacterial potency in physiological concentrations of NaCl.
Thus, the mechanism of antibacterial action of rattusin is most
likely to be different from that of other defensins and defensin-
related peptides.
Given the location of their genes within the -defensin gene
cluster (9, 24) and their separate existence in rats and mice, rat-
tusin and CRS peptides must have evolved independently from
-defensins after the divergence of rats and mice 33 million years
ago (48). Interestingly, in contrast to rats harboring 12 -de-
fensins and one -defensin-related rattusin, mice produce at least
26 functional -defensins (cryptdins) and 12 -defensin-related
CRS peptides (9, 24), with some even present in a strain-specific
manner (49). On the other hand, humans synthesize only six func-
tional -defensins with a -defensin pseudogene and no -defen-
sin-related sequences (24). Phylogenetic analysis revealed that
mammalian -defensins mostly form species-specific clusters
(24), implying that most of these genes may have undergone in-
dependent duplications and diversifications within each species
after divergence from a common ancestor.
Mammalian -defensins and their related peptides are antimi-
crobial components of dense core granules of small intestinal Pan-
eth cells or of circulating neutrophils (5–7). Albeit with direct,
broad-spectrum antimicrobial activities, many peptides vary in
antimicrobial potency, spectrum, and mechanism (50, 51). For
example, HD5 and HD6 coexist in human Paneth cells; however,
HD5 is bactericidal whereas HD6 is largely inactive (51). HD5 kills
bacteria through physical membrane disruption, while HD6 pro-
tects the host by forming nanonets that entrap bacteria and keep
them from translocating across the intestinal epithelial barrier
(45). Given the differences in the expression patterns and antimi-
crobial properties of individual -defensins and defensin-related
peptides, it is tempting to speculate that the presence of a distinct
repertoire of such peptides in each species may confer a distinct
host defense capacity, ensuring optimal host protection from in-
vading pathogens in diverse environmental niches.
The preferential expression of a large number of-defensins in
Paneth cells of the distal small intestine but not the colon may help
explain, in part, the fact that the bacterial population in the small
intestine is 104- to 106-fold smaller than that in the colon (52).
Furthermore, intestinal defensins play a profound role in dictat-
ing the makeup of the ileal microflora, as evidenced by obvious
alternations in the composition of the microbiota of the small
intestine both in mice overexpressing HD5 and in mice deficient
in the Paneth cell -defensin convertase MMP7 (19). Because the
reduction of disulfide bonds profoundly affects the biological ac-
tivities of defensins (21) and some defensins may be naturally
present in the reduced form by thioredoxin in the colon (46), we
speculate that the repertoire of intestinal defensins may influence
the composition of microflora in the large intestine as well.
In summary, rattusin is a rat -defensin-related peptide and is
preferentially expressed in Paneth cells of the distal small intestine.
Unlike most other - and -defensins that are inactivated by
mono- or divalent cations, rattusin stands out as a unique defen-
sin-related peptide, possessing potent, salt-independent bacteri-
cidal activities, with essentially no toxicity to mammalian cells.
Functionally and structurally distinct from any other intestinal
defensins, rattusin may confer on rats unique host defense mech-
anisms. Furthermore, the desirable antibacterial properties of rat-
tusin may be further exploited for the treatment of cystic fibrosis
and Crohn’s disease, where impairment of the antibacterial activ-
ity or synthesis of defensins proves detrimental to the host (18,
53). Coupled with its low cytotoxicity, rattusin may have potential
for use in the treatment of both topical and systemic infections.
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